Adrenomedullin: a smart road from pheochromocytoma to treatment of pulmonary hypertension

Westphal M., Booke M., Dinh-Xuan A.T.

Source: Eur Respir J 2004; 24 : 518-520
Journal Issue: October

PDF journal article, handout or slidesFull text journal article

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Westphal M., Booke M., Dinh-Xuan A.T.. Adrenomedullin: a smart road from pheochromocytoma to treatment of pulmonary hypertension. Eur Respir J 2004; 24 : 518-520

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
When is pulmonary hypertension not pulmonary hypertension?
Source: Eur Respir J 2001; 18: Suppl. 33, 522s
Year: 2001

Apelin improves cardiac output in patients with pulmonary arterial hypertension
Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights
Year: 2015

?-blockers in pulmonary arterial hypertension: generation might matter
Source: Eur Respir J 2016; 47: 682-684
Year: 2016


Riociguat for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Real-life data from the EXPERT registry
Source: International Congress 2015 – Pulmonary hypertension: new treatment insights
Year: 2015



Goal-oriented therapy in paediatric pulmonary arterial hypertension: are we ready?
Source: Eur Respir J 2014; 44: 1404-1407
Year: 2014


Pulmonary arterial hypertension: treatment options
Source: International Congress 2018 – ME10 Pulmonary arterial hypertension: treatment options FULLY BOOKED
Year: 2018


The dopaminergic system in pulmonary hypertension
Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension II
Year: 2013

Medical treatment of pulmonary arterial hypertension
Source: ISSN=1025-448x, ISBN=1-904097-29-4, page=31
Year: 2003

COVID-19 in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a reference centre survey
Source: ERJ Open Res, 6 (4) 00520-2020; 10.1183/23120541.00520-2020
Year: 2020



Experience with pulmonary selective vasodilator treatment in COPD with severe pulmonary hypertension
Source: Annual Congress 2011 - Pulmonary hypertension in hypoxic lung disease
Year: 2011

Acute vasodilator testing in idiopathic pulmonary arterial hypertension: must we take NO for the answer?
Source: Eur Respir J 2009; 33: 1247-1249
Year: 2009


Long-term safety of a new formulation of epoprostenol in pulmonary arterial hypertension
Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment
Year: 2013

Interventional treatment of pulmonary hypertension: where are we now?
Source: Virtual Congress 2020 – Breathing disorders and cardiovascular diseases
Year: 2020


Pulmonary hypertension and pulmonary arterial hypertension: a clarification is needed
Source: Eur Respir J 2010; 36: 986-990
Year: 2010


Pulmonary arterial hypertension: current therapies
Source: ISSN=1025-448x, ISBN=1-904097-31-6, page=57
Year: 2004

The vascular bed in COPD: pulmonary hypertension and pulmonary vascular alterations
Source: Eur Respir Rev 2014; 23: 350-355
Year: 2014



LATE-BREAKING ABSTRACT: Peak oxygen consumption improves in inoperable, but not operable, chronic thromboembolic pulmonary hypertension after treatment with pulmonary arterial hypertension drugs
Source: Annual Congress 2013 –New physiologic boundaries
Year: 2013


The endothelin system in pulmonary and renal vasculopathy: les liaisons dangereuses
Source: Eur Respir Rev 2009; 18: 260-271
Year: 2009



The new definition of pulmonary hypertension
Source: Eur Respir J 2009; 34: 790-791
Year: 2009


Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children
Source: Eur Respir J 2011; 37: 70-77
Year: 2011